Publication
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantBRAF V600Kcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23020132
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID6940In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monot… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC | civic |
| BRAF V600E + BRAF V600K1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID93This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma. Cutaneous squamous-cell carcinoma was… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC | civic |
| BRAF V600K1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID6941In this Phase I and II study (NCT01072175), patients with metastatic melanoma were treated with either a combination of dabrafenib and trametinib or dabrafenib monotherapy. Among patients with the V60… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC | civic |
| BRAF Non-V600 + BRAF V600R1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 1 | submitted | EID11308In this phase 1/2, open-label study 247 patients with metastatic melanoma and BRAF V600 mutations V600 (only one patient with a non-V600E/V600K with a BRAF V600R) were enrolled. Part 1 evaluated the p… (full text at CIViC) PMID 23020132 · Flaherty et al., 2012 · Open in CIViC | civic |